Severe acne vulgaris is a chronic inflammatory skin condition characterized by deep cysts, nodules, and persistent inflammation that can lead to scarring and psychological distress. As per Dumitrița Lenuța Guguluș et al., 2025, the global prevalence of acne is approximately 9.4%, with acne vulgaris affecting up to 57.8% of individuals aged up to 24 years. According to the Severe Acne Vulgaris Pipeline Analysis by Expert Market Research, growing research in novel retinoids, anti-inflammatory biologics, and hormonal therapies is driving innovation. Increasing awareness, improved dermatological care, and advancements in targeted drug development are expected to fuel market growth in the coming years.
The Severe Acne Vulgaris Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into severe acne vulgaris drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for severe acne vulgaris. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The severe acne vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from severe acne vulgaris.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to severe acne vulgaris.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Acne vulgaris is a chronic form of acne, characterized by the formation of inflammatory or non-inflammatory skin lesions. It commonly affects the face, but it may spread to the neck, back or chest in some cases. It is commonly triggered by a bacterial species called Cutibacterium acnes and mostly affects young adults. Common symptoms include excessive sebum production, follicular plugging with keratinocytes and colonization by the bacteria. Hormonal imbalance, high sweating, occlusive cosmetics or skin care can be other causes of acne vulgaris.
Treatment for severe acne vulgaris depends on skin type, area and type of lesions as well as grade of acne. Acne is graded in the severe category when the total lesion count is more than 125, the total inflammatory count is greater than 50 and the total comedo is higher than 100. In October 2023, Bausch Health’s Cabtreo (triple combination gel) for treating acne in individuals aged 12 or above. Such drug approvals are expected to stimulate more research, thereby, impacting the drug pipeline for severe acne vulgaris positively.
This section of the report covers the analysis of severe acne vulgaris drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for severe acne vulgaris. There are around 47 drugs in phase II of severe acne vulgaris drugs.
The drug molecules categories covered under severe acne vulgarispipeline analysis include antibiotics, retinoids, hormonal agents, and anti-inflammatory drugs. Antibiotics like doxycycline, minocycline, and tetracycline may be advised for treating bacterial infections while anti-inflammatory drugs such as corticosteroids can be taken orally or injected into the acne lesion. Drugs are based on the patient’s profile and the severity of the condition.
The EMR report for the severe acne vulgarisdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in severe acne vulgaris clinical trials:
Pfizer's PF-05175157 is in Phase 2 of a 6-week randomized, double-blind, placebo-controlled study. It is under evaluation for its safety and tolerability against treating moderate to severe acne vulgaris in adults.
RA-18C3 is a human monoclonal antibody, currently in Phase 2 of a 91-day open label trial for treating moderate to severe acne vulgaris in subjects. Sponsored by Janssen Research & Development, LLC, the participants will receive doses on days 0, 21, and 42 (with a total of 3 injections).
FMX101 is a topical foam that contains 4% minocycline. Sponsored by Vyne Therapeutics, Inc., it is Phase 3 of a randomized, double-blind, vehicle-controlled study to investigate its safety and efficacy for treating moderate-to-severe acne vulgaris.
Sponsored by Novan Inc., it is Phase 1 of a single-center, open-label study. The topical is under investigation to treat adolescents with moderate to severe acne vulgaris. The study involves taking blood samples from the participants on Day 1 and Day 21 to characterize systemic exposure to hMAP3 and nitrate.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Severe Acne Vulgaris Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for severe acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within severe acne vulgaris pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share